Department of Natural Medicinal Chemistry , China Pharmaceutical University , Nanjing 210009 , China.
Department of Pharmaceutical Analysis , China Pharmaceutical University , Nanjing 210009 , China.
ACS Appl Mater Interfaces. 2020 Feb 5;12(5):5680-5694. doi: 10.1021/acsami.9b23325. Epub 2020 Jan 24.
Photodynamic therapy (PDT), a clinically approved cancer treatment, has faced many drawbacks that restricted its applications. For example, the hypoxia-induced elevated hypoxia-inducible factor-1α (HIF-1α) may desensitize tumors to PDT, and the high concentration of glutathione (GSH) in cancer cells can also neutralize the generated reactive oxygen species (ROS) during PDT, resulting in insufficient therapy. Moreover, extra probes for imaging-guided visualization therapy are always needed to track drug release or distribution, while it may decrease the drug loading of the drug delivery system (DDS). In the present study, we have designed and prepared a novel multifunctional combined therapy nanoparticle (ZnPc@Cur-S-OA NPs), in which curcumin (Cur) was not only used as a chemotherapy drug to achieve a combination therapy with PDT via downregulating HIF-1α and depleting GSH in B16F10 cells but also designed as a small-molecule ROS-triggered release prodrug to deliver the photosensitizer (PS). The red fluorescence of PS in the nanoparticles (NPs) can be used to track the NPs distribution, while the green fluorescence of Cur showed an "OFF-ON" activation, which enables additional imaging and real-time self-monitoring capabilities. These results proved that the prepared combined therapy NPs were more effective to inhibit the growth of B16F10 mouse melanoma tumor than was monotherapy without eliciting systemic toxicity either or , which indicated the combined therapy NPs as an effective way to improve the PDT efficacy via downregulation of HIF-1α and depletion of GSH. Thus, the strategy of using a multifunctional natural product as the stimuli-responsive carrier as well as the synergist with PDT for enhancing antitumor efficacy via multiple pathways may open an alternative avenue to fabricate new self-delivery combination therapy nanodrugs. Besides, the fluorescence emitted from the drug can be used for real-time self-monitoring of drug release and distribution, which has great potential in clinic to adjust the administration dose and irradiation time for different tumor types and stages for individual therapy.
光动力疗法(PDT)是一种临床认可的癌症治疗方法,但存在许多局限性。例如,缺氧诱导的缺氧诱导因子-1α(HIF-1α)升高可能使肿瘤对 PDT 产生耐药性,癌细胞中高浓度的谷胱甘肽(GSH)也可以中和 PDT 过程中产生的活性氧(ROS),导致治疗效果不足。此外,还需要额外的探针进行成像引导可视化治疗,以跟踪药物释放或分布,但这可能会降低药物递送系统(DDS)的药物载药量。在本研究中,我们设计并制备了一种新型多功能联合治疗纳米颗粒(ZnPc@Cur-S-OA NPs),其中姜黄素(Cur)不仅被用作化疗药物,通过下调 B16F10 细胞中的 HIF-1α 和耗尽 GSH 来实现与 PDT 的联合治疗,而且还被设计为小分子 ROS 触发的释放前药来递送光敏剂(PS)。纳米颗粒(NPs)中 PS 的红色荧光可用于跟踪 NPs 的分布,而 Cur 的绿色荧光显示出“OFF-ON”激活,从而提供了额外的成像和实时自我监测功能。这些结果证明,与单一疗法相比,制备的联合治疗纳米颗粒更有效地抑制 B16F10 小鼠黑色素瘤肿瘤的生长,而不会引起全身毒性。这表明联合治疗纳米颗粒是一种通过下调 HIF-1α 和耗尽 GSH 来提高 PDT 疗效的有效方法。因此,使用多功能天然产物作为刺激响应载体以及与 PDT 协同作用通过多种途径增强抗肿瘤疗效的策略可能为制造新型自递送联合治疗纳米药物开辟了另一种途径。此外,药物发出的荧光可用于实时自我监测药物的释放和分布,这在临床上具有很大的潜力,可以根据不同的肿瘤类型和阶段调整个体治疗的给药剂量和照射时间。
ACS Appl Mater Interfaces. 2022-2-2
Nanomedicine (Lond). 2024
Pharmaceuticals (Basel). 2024-2-1
J Funct Biomater. 2023-8-2
Molecules. 2023-5-9